448 related articles for article (PubMed ID: 25654354)
1. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Boeree MJ; Diacon AH; Dawson R; Narunsky K; du Bois J; Venter A; Phillips PP; Gillespie SH; McHugh TD; Hoelscher M; Heinrich N; Rehal S; van Soolingen D; van Ingen J; Magis-Escurra C; Burger D; Plemper van Balen G; Aarnoutse RE;
Am J Respir Crit Care Med; 2015 May; 191(9):1058-65. PubMed ID: 25654354
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Aarnoutse RE; Kibiki GS; Reither K; Semvua HH; Haraka F; Mtabho CM; Mpagama SG; van den Boogaard J; Sumari-de Boer IM; Magis-Escurra C; Wattenberg M; Logger JGM; Te Brake LHM; Hoelscher M; Gillespie SH; Colbers A; Phillips PPJ; Plemper van Balen G; Boeree MJ;
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827417
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
[TBL] [Abstract][Full Text] [Related]
4. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
[TBL] [Abstract][Full Text] [Related]
5. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Padmapriyadarsini C; Bhavani PK; Natrajan M; Ponnuraja C; Kumar H; Gomathy SN; Guleria R; Jawahar SM; Singh M; Balganesh T; Swaminathan S
BMJ Open; 2019 Mar; 9(3):e024363. PubMed ID: 30826761
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
Velásquez GE; Brooks MB; Coit JM; Pertinez H; Vargas Vásquez D; Sánchez Garavito E; Calderón RI; Jiménez J; Tintaya K; Peloquin CA; Osso E; Tierney DB; Seung KJ; Lecca L; Davies GR; Mitnick CD
Am J Respir Crit Care Med; 2018 Sep; 198(5):657-666. PubMed ID: 29954183
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Jindani A; Doré CJ; Mitchison DA
Am J Respir Crit Care Med; 2003 May; 167(10):1348-54. PubMed ID: 12519740
[TBL] [Abstract][Full Text] [Related]
9. A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.
Svensson RJ; Aarnoutse RE; Diacon AH; Dawson R; Gillespie SH; Boeree MJ; Simonsson USH
Clin Pharmacol Ther; 2018 Apr; 103(4):674-683. PubMed ID: 28653479
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
[TBL] [Abstract][Full Text] [Related]
11. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
[TBL] [Abstract][Full Text] [Related]
12. Phase II dose-ranging trial of the early bactericidal activity of PA-824.
Diacon AH; Dawson R; du Bois J; Narunsky K; Venter A; Donald PR; van Niekerk C; Erondu N; Ginsberg AM; Becker P; Spigelman MK
Antimicrob Agents Chemother; 2012 Jun; 56(6):3027-31. PubMed ID: 22430968
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
14. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
15. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
Roy V; Tekur U; Chopra K
Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
[TBL] [Abstract][Full Text] [Related]
18. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
19. [Short-course chemotherapy of tuberculosis with pyrazinamide].
Asai S; Futsuki Y; Tomari S; Araki J
Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
[TBL] [Abstract][Full Text] [Related]
20. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
Al-Dossary FS; Ong LT; Correa AG; Starke JR
Pediatr Infect Dis J; 2002 Feb; 21(2):91-7. PubMed ID: 11840073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
